Finlepsin retard 50 tablets 200mg & 400mg Сarbamazepine Финлепсин Epilepsy & Neuralgia

Finlepsin Indications

- epilepsy: partial seizures with elementary symptoms (Jackson's seizures); partial seizures with complex symptomatology (psychomotor seizures); grand mal seizures, especially focal nature (nocturnal epilepsy, diffuse epilepsy); mixed forms of epilepsy;

- trigeminal neuralgia;

- genuinnaya glossopharyngeal neuralgia;

- pain of diabetic neuropathy;

- non-epileptic seizures in patients with multiple sclerosis, such as trigeminal neuralgia, tonic seizures, paroxysmal dysarthria and ataxia, paroxysmal paraesthesia and attacks of pain;

- prevention of the development of seizures during alcohol withdrawal syndrome;

- prevention of manic-depressive phases in ineffective therapy with lithium, when patients experience rapid changes in phase when taking lithium or if lithium is contraindicated.

Contradictions

bone marrow, bone marrow suppression function in the patient's history;
AV-block;
known hypersensitivity to carbamazepine, tricyclic antidepressants, or other components of the drug;
acute intermittent porphyria;
concomitant treatment with an inhibitor of MAO;
voriconazole concomitant treatment, since it may cause treatment failure;
children under 6 years.

Dosage & Administartion

Finlepsin retard drug treatment begin carefully prescribed medication in low doses for each patient depending on the type and severity of the disease. Thereafter, the dosage is gradually increased until the maintenance dose is most effective.

The optimum dose for the patient, especially in combination therapy, it is determined by the level in blood plasma. According to experience, the therapeutic drug concentration Finlepsin retard plasma is 4-12 mcg / ml.

Replacement of one antiepileptic drug Finlepsin retard should be carried out gradually, reducing the dose of the previously used drug. If possible, use only antiepileptic drug monotherapy. Treatment is carried out under the supervision of a physician.